Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate Kit
Product Images NDC 68462-849

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate (NDC 68462-849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blisterimage (Blisterimage)

An instructional diagram showing a four-week oral contraceptive kit blister pack layout for Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate capsules. The calendar days Sunday through Saturday are labeled across four rows representing weeks, with pill positions indicated. Instructions show starting day guidance and pill-taking direction from left to right each week, with areas for expiration date and lot number.*

FDA Label Image

Carton (Carton)

Packaging label for Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate capsules, 1 mg/20 mcg strength, in a kit dosage form. The label states it contains 1 blister of 28 soft gelatin capsules providing 24 days of active therapy. The labeler is Glenmark Pharmaceuticals Inc., USA, with manufacturing by Cyndea Pharma S.L., Spain. The carton size is 68 mm x 26 mm x 100 mm and includes safety, storage, and dosage instructions.*

FDA Label Image

Ethinylestradiol (Ethinylestradiol)

Chemical structure diagram of the active ingredient Ethinyl Estradiol showing its molecular structure with labeled atoms and bonds.*

FDA Label Image

Figure1 (Figure1)

A forest plot chart titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' showing effect estimates comparing risk of breast cancer for ever use and current use of combined oral contraceptives (COC) versus never use. The chart lists several studies with associated effect estimates and confidence intervals, displaying odds ratios (OR), relative risks (RR), and hazard ratios (HR) for each study along a horizontal axis labeled 'Effect Estimate' ranging from -1.50 to 2.00.*

FDA Label Image

Figure2 (Figure2)

A line graph showing norethindrone concentration (pg/mL) over time (hours) for Day 1 and Day 24. Two curves are plotted, with norethindrone concentration peaking early and then declining over 60 hours. The Day 24 curve shows higher concentrations compared to Day 1 throughout the time period.*

FDA Label Image

Figure3 (Figure3)

A pharmacokinetic line graph depicting ethinyl estradiol concentration (pg/mL) over time (hours) for Day 1 and Day 24. The x-axis shows time from 0 to 60 hours, and the y-axis shows ethinyl estradiol concentration from 0 to 80 pg/mL. Data points for Day 1 and Day 24 are connected with solid and dotted lines respectively, demonstrating peak concentrations occurring shortly after administration and a decline over time.*

FDA Label Image

Flowchart (Flowchart)

A vertical efficacy chart showing pregnancy rates per 100 women per year corresponding to different birth control methods. The chart ranges from fewer than 1 pregnancy to 85 or more pregnancies with methods listed including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, fertility awareness, spermicide, withdrawal, and no birth control.*

FDA Label Image

Glenmarklogo (Glenmarklogo)

FDA Label Image

Logo (Logo)

FDA Label Image

Norethindroneacetate (Norethindroneacetate)

Chemical structure diagram of the active ingredient Norethindrone Acetate, showing molecular bonds and functional groups in a steroid framework.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.